Inhibition of the aminopeptidase activity of FAP resulted in decreased tumor growth and was associated with an accumulation of collagen, decreased numbers of myofibroblasts, and decreased tumor vascularization in preclinical models [21], however no objective clinical responses were observed in clinical trials [23]. The gene discussed is CPQ; the disease is neoplasm.